Interferon-gamma is quintessential for NOS2 and COX2 expression in ER

Female Humans CD8-Positive T-Lymphocytes Cell Line, Tumor Cyclooxygenase 2 / genetics Interferon-gamma / genetics Nitric Oxide Synthase Type II / genetics Triple Negative Breast Neoplasms / genetics Tumor Microenvironment / genetics Tumor Necrosis Factor-alpha / metabolism

Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
11 05 2023
Historique:
received: 05 12 2022
accepted: 24 04 2023
revised: 20 04 2023
medline: 15 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: epublish

Résumé

A strong correlation between NOS2 and COX2 tumor expression and poor clinical outcomes in ER breast cancer has been established. However, the mechanisms of tumor induction of these enzymes are unclear. Analysis of The Cancer Genome Atlas (TCGA) revealed correlations between NOS2 and COX2 expression and Th1 cytokines. Herein, single-cell RNAseq analysis of TNBC cells shows potent NOS2 and COX2 induction by IFNγ combined with IL1β or TNFα. Given that IFNγ is secreted by cytolytic lymphocytes, which improve clinical outcomes, this role of IFNγ presents a dichotomy. To explore this conundrum, tumor NOS2, COX2, and CD8

Identifiants

DOI: 10.1038/s41419-023-05834-9 PMID: 37169743 PMC: PMC10175544
pubmed: 37169743
doi: 10.1038/s41419-023-05834-9
pii: 10.1038/s41419-023-05834-9
pmc: PMC10175544
doi:

Substances chimiques

Cyclooxygenase 2 EC 1.14.99.1
Interferon-gamma 82115-62-6
Nitric Oxide Synthase Type II EC 1.14.13.39
NOS2 protein, human EC 1.14.13.39
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

319

Subventions

Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210181
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA238727
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA253553
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

Redox Biol. 2022 Dec;58:102529
pubmed: 36375380
Mol Med. 2000 May;6(5):347-73
pubmed: 10952018
Mol Cancer Res. 2012 Sep;10(9):1203-15
pubmed: 22878588
Front Oncol. 2022 Jan 19;11:791696
pubmed: 35127497
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8137-41
pubmed: 8058769
Mod Pathol. 2022 May;35(5):601-608
pubmed: 34839351
Mol Neurodegener. 2014 Nov 17;9:50
pubmed: 25403885
J Clin Invest. 2010 Nov;120(11):3843-54
pubmed: 20978357
Curr Oncol. 2022 Sep 23;29(10):6847-6863
pubmed: 36290817
Cancer Med. 2021 Jun;10(12):3905-3918
pubmed: 33955198
Oncoimmunology. 2018 Jul 30;7(9):e1484979
pubmed: 30228955
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6323-8
pubmed: 24733928
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):13030-13035
pubmed: 29087320
Mod Pathol. 2005 Jan;18(1):26-35
pubmed: 15332092
Br J Pharmacol. 2019 Jan;176(2):155-176
pubmed: 30152521
J Clin Invest. 2019 Apr 1;129(4):1785-1800
pubmed: 30753167
BMC Cancer. 2010 Nov 15;10:626
pubmed: 21078168
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):622-631
pubmed: 27979806
Br J Pharmacol. 1998 Sep;125(1):193-201
pubmed: 9776360
Clin Cancer Res. 2019 May 1;25(9):2769-2782
pubmed: 30670488
Methods Mol Biol. 2020;2055:585-592
pubmed: 31502170
Front Immunol. 2022 Oct 20;13:1039565
pubmed: 36341357
Semin Cancer Biol. 2015 Apr;31:43-51
pubmed: 25153354
Redox Biol. 2020 Jan;28:101354
pubmed: 31683257
Breast Cancer Res. 2015 Feb 22;17:25
pubmed: 25849745
For Immunopathol Dis Therap. 2012;3(2):117-124
pubmed: 23543871
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Biomark Res. 2020 Sep 29;8:49
pubmed: 33005420
Nat Protoc. 2007;2(2):329-33
pubmed: 17406593
Hypertension. 2017 Jun;69(6):1092-1103
pubmed: 28373589
Antioxid Redox Signal. 2017 Jun 10;26(17):963-965
pubmed: 28506076
Crit Rev Oncog. 2016;21(5-6):333-351
pubmed: 29431082
Antioxidants (Basel). 2022 Feb 22;11(3):
pubmed: 35326089
Sci Transl Med. 2021 Dec 15;13(624):eabj5070
pubmed: 34910551
Redox Biol. 2015 Aug;5:413
pubmed: 28162269
Cancer Res. 2018 Sep 15;78(18):5243-5258
pubmed: 30012670
Biomolecules. 2023 Feb 07;13(2):
pubmed: 36830680
Antioxid Redox Signal. 2017 Jun 20;26(18):1044-1058
pubmed: 27464521
Breast Cancer Res. 2012 Sep 12;14(5):R125
pubmed: 22971289
Int J Mol Sci. 2019 Jun 20;20(12):
pubmed: 31226744
JCI Insight. 2022 Feb 8;7(3):
pubmed: 35132960

Auteurs

Robert Y S Cheng (RYS)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
ORCID: 0000-0003-0287-6439

Lisa A Ridnour (LA)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
ORCID: 0000-0001-9446-8349

Adelaide L Wink (AL)

Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA.

Ana L Gonzalez (AL)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

Elise L Femino (EL)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

Helene Rittscher (H)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

Veena Somasundaram (V)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

William F Heinz (WF)

Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA.
ORCID: 0000-0002-6194-0536

Leandro Coutinho (L)

Center for Translational Research in Oncology, ICESP/HC, Faculdade de Medicina da Universidade de São Paulo; and Comprehensive Center for Precision Oncology, Universidade de São Paulo, São Paulo, SP, Brazil.

M Cristina Rangel (MC)

Center for Translational Research in Oncology, ICESP/HC, Faculdade de Medicina da Universidade de São Paulo; and Comprehensive Center for Precision Oncology, Universidade de São Paulo, São Paulo, SP, Brazil.
ORCID: 0000-0002-8002-9617

Elijah F Edmondson (EF)

Molecular Histopathology Laboratories, Leidos Biomedical Research Inc. for NCI, Frederick, MD, USA.

Donna Butcher (D)

Molecular Histopathology Laboratories, Leidos Biomedical Research Inc. for NCI, Frederick, MD, USA.

Robert J Kinders (RJ)

Office of the Director, Division of Cancer Treatment and Diagnosis, NCI, Frederick, MD, USA.

Xiaoxian Li (X)

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.

Stephen T C Wong (STC)

Systems Medicine and Bioengineering Department, Houston Methodist Neal Cancer Center, Houston Methodist Hospital and Weill Cornell Medicine, Houston, TX, USA.

Daniel W McVicar (DW)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

Stephen K Anderson (SK)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

Milind Pore (M)

Imaging Mass Cytometry Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Stephen M Hewitt (SM)

Laboratory of Pathology CCR, NCI, NIH, Bethesda, MD, USA.
ORCID: 0000-0001-8283-1788

Timothy R Billiar (TR)

Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA.
ORCID: 0000-0002-2949-0811

Sharon A Glynn (SA)

Discipline of Pathology, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland.

Jenny C Chang (JC)

Mary and Ron Neal Cancer Center, Houston Methodist Hospital and Weill Cornell Medicine, Houston, TX, USA.

Stephen J Lockett (SJ)

Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA.
ORCID: 0000-0002-2010-9914

Stefan Ambs (S)

Laboratory of Human Carcinogenesis, CCR, NCI, NIH, Bethesda, MD, USA.
ORCID: 0000-0001-7651-9309

David A Wink (DA)

Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA. wink@mail.nih.gov.
ORCID: 0000-0002-5652-7480

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Cyclooxygenase 2 › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Facteurs d'activation des macrophages › Interféron gamma › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéines liant le poly-adp-ribose › Nitric oxide synthase type II › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Interferon-gamma is quintessential for NOS2...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › Interferon-gamma is quintessential for NOS2...